New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For VVUS;OREX;ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
09:17 EDTOREXOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTOREXOrexigen announces allowance of new U.S. patent for Contrave
Orexigen Therapeutics announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the FDA.
November 18, 2014
07:37 EDTARNAStifel to hold a conference
Subscribe for More Information
November 10, 2014
07:05 EDTOREXOrexigen reports Q3 EPS 9c, consensus (13c)
Reports Q3 revenue $30.9M, consensus $8.93M; This increase in 2014 was due to recognition of two regulatory/development milestones, consisting of $20.0 million due upon regulatory approval in the U.S. and $10.0 million due upon the delivery of Contrave launch supplies to Takeda.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use